KRICILA Injection combines Imipenem 500 mg and Cilastatin 500 mg, a powerful broad-spectrum antibiotic used to treat serious bacterial infections. Imipenem works by inhibiting bacterial cell wall synthesis, while Cilastatin prevents the breakdown of Imipenem in the kidneys, ensuring maximum effectiveness. KRICILA is administered intravenously or intramuscularly under medical supervision.
Countries Served
Products Developed
Research Scientists
Years of Excellence
Join us in our mission to improve lives through innovative pharmaceutical products.